A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.
about
Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternativesAdjunctive aripiprazole in risperidone-induced hyperprolactinaemia: double-blind, randomised, placebo-controlled trial.Strategies for Early Non-response to Antipsychotic Drugs in the Treatment of Acute-phase SchizophreniaThe effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review.Effects of adjunctive aripiprazole on sexual functioning in patients with major depressive disorder and an inadequate response to standard antidepressant monotherapy: a post hoc analysis of 3 randomized, double-blind, placebo-controlled studies.World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance.Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trialsTreating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin).Using aripiprazole to reduce antipsychotic-induced hyperprolactinemia: meta-analysis of currently available randomized controlled trialsA Non-Interventional Naturalistic Study of the Prescription Patterns of Antipsychotics in Patients with Schizophrenia from the Spanish Province of Tarragona.Role of aripiprazole in treatment-resistant schizophrenia.Safety and tolerability of antipsychotic polypharmacy.Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it?Adjunctive Aripiprazole Treatment for Risperidone-Induced Hyperprolactinemia: An 8-Week Randomized, Open-Label, Comparative Clinical TrialProlactin serum concentrations during aripiprazole treatment in youth.Long-term antipsychotic polypharmacy: how does it start, why does it continue?Effect of aripiprazole on cognitive function and hyperprolactinemia in patients with schizophrenia treated with risperidoneEfficacy and Tolerability of Paliperidone Extended-release in the Treatment of First-episode Psychosis: An Eight-week, Open-label, Multicenter Trial.Treatment of hyperprolactinemia and gynecomastia with adjunctive aripiprazole in 2 men receiving long-acting injectable antipsychotics.Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysisAntipsychotics and hyperprolactinaemia: mechanisms, consequences and management.Pharmacotherapy for treatment-refractory schizophrenia.Antipsychotic polypharmacy in schizophrenia: benefits and risks.Antipsychotic-induced hyperprolactinaemia.Aripiprazole treatment for patients with schizophrenia: from acute treatment to maintenance treatment.Aripiprazole: a review of its use in the management of schizophrenia in adults.Is rational antipsychotic polytherapy feasible? A selective review.Risperidone and pulmonary embolism: a harmful association? Case series and review of the literature.Practical pharmacotherapy for acute schizophrenia patients.Antipsychotic combinations for schizophrenia.Antipsychotic Management of Schizoaffective Disorder: A Review.Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials.Serum prolactin levels and sexual dysfunction in patients with schizophrenia treated with antipsychotics: comparison between aripiprazole and other atypical antipsychotics.Antipsychotic polypharmacy and augmentation strategies prior to clozapine initiation: a historical cohort study of 310 adults with treatment-resistant schizophrenic disorders.Management of common adverse effects of antipsychotic medications
P2860
Q26863435-0F6515CF-4B11-464A-9CD9-AA12CAC392D5Q30490025-07CE0D56-245F-429E-805E-DF9A7A741008Q33618932-2A1049A3-5DB7-431D-BF3A-DB1916948F94Q33619940-B3EB94AB-2FFD-4F39-80F6-90D5F9D2854EQ34027550-A6C446AC-8FB1-4109-B7D8-D5742871C917Q34640811-E8508D63-CA38-4B32-B160-A05A55F51871Q34925151-D135659A-4BA4-4B37-B8DA-F4149001B29FQ34966395-BC903C18-CBF4-4F2E-8D6D-DACAEF41C450Q35214820-3EC9EE87-DDBF-4614-A1C4-F87547BC09BBQ35795401-7293E44C-7B5A-4717-89E5-23E73D9EBA71Q36026776-E85AA645-C888-4415-901A-1610F70B00A3Q36062421-A8C80966-F138-4622-BDBD-1207FCA7DAC3Q36119267-6E9CAC2F-1173-4895-B3FA-301910326B94Q36136886-92B2B24D-FD60-473E-AF3A-FD1C9DDA6998Q36853126-0F9C438A-2591-4E2A-9844-82776B4E0A11Q37079008-24E5F063-88E6-4842-A42F-C7D8BD52DCD7Q37155297-40BEDB5E-0BEF-45E5-B7A3-F0430C1CB475Q37160642-8CBD9E94-7C5C-4F57-BD1A-27D8B668B7DFQ37407131-F8485B38-38AC-44CE-B3F5-D94E31CBFB94Q37609168-05464337-AA6E-4328-AC30-8FD44FFC096AQ37747570-F72F1034-7BD6-4D8B-B87B-7C59E4EE7F21Q37831352-A9191ED5-47B0-4787-BD20-15DFC673C6C8Q37863093-BEEEE7F2-5C50-46CA-B5D5-8AB9FC0F3CFEQ37895702-7EADA9B3-0984-4A45-95A9-013A953DD919Q37947687-69865C82-B49A-4BBC-BE90-0BF91A82D992Q37980517-1FDD1F32-64B1-4F76-AD7E-2577F3488011Q37993473-035CF0A5-FC40-4839-B65D-F574B10A97DDQ38257153-955D388B-66DD-4474-82E3-984F84EA680AQ38513767-4E82EEB6-058A-4FC7-9E0E-43663F6EE84CQ38704394-5AD159EA-1AB0-48C8-88FE-63F8DEB00113Q38755501-212F0688-4833-485A-BA6D-0D91157D0DDCQ38769838-63DC30AD-3FC3-4E42-8DDA-68AA2AC2A96CQ47144902-9D547F75-4275-4161-946E-93EE77CDE673Q53169797-AA89C80E-2A98-4E47-85B5-AFBE10A4DAB4Q58760350-BE75731D-DA72-4E36-94C1-EBEEFFAD0A2F
P2860
A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
A multicenter, randomized, dou ...... ne or risperidone monotherapy.
@en
type
label
A multicenter, randomized, dou ...... ne or risperidone monotherapy.
@en
prefLabel
A multicenter, randomized, dou ...... ne or risperidone monotherapy.
@en
P2093
P50
P921
P356
P1476
A multicenter, randomized, dou ...... ne or risperidone monotherapy.
@en
P2093
Andrei Pikalov
Christoph U Correll
Estelle Vester-Blokland
Sheila Assunção-Talbott
Stephen R Marder
William H Carson
P304
P356
10.4088/JCP.09M05154YEL
P577
2009-10-01T00:00:00Z